Human immunodeficiency virus type 1 latency model for high-throughput screening

被引：18

作者：

Micheva-Viteva, S ^{[1
]}

Pacchia, AL ^{[1
]}

Ron, Y ^{[1
]}

Peltz, SW ^{[1
]}

Dougherty, JP ^{[1
]}

机构：

[1] UMDNJ, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 12期

关键词：

D O I：

10.1128/AAC.49.12.5185-5188.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

引用

页码：5185 / 5188

页数：4

共 19 条

[1] SECRETED PLACENTAL ALKALINE-PHOSPHATASE - A POWERFUL NEW QUANTITATIVE INDICATOR OF GENE-EXPRESSION IN EUKARYOTIC CELLS [J].

BERGER, J ;

HAUBER, J ;

HAUBER, R ;

GEIGER, R ;

CULLEN, BR .

GENE, 1988, 66 (01) :1-10

[2] Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy [J].

Chun, TW ;

Davey, RT ;

Ostrowski, M ;

Justement, JS ;

Engel, D ;

Mullins, JI ;

Fauci, AS .

NATURE MEDICINE, 2000, 6 (07) :757-761

[3] HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J].

Davey, RT ;

Bhat, N ;

Yoder, C ;

Chun, TW ;

Metcalf, JA ;

Dewar, R ;

Natarajan, V ;

Lempicki, RA ;

Adelsberger, JW ;

Millers, KD ;

Kovacs, JA ;

Polis, MA ;

Walker, RE ;

Falloon, L ;

Masur, H ;

Gee, D ;

Baseler, M ;

Dimitrov, DS ;

Fauci, AS ;

Lane, HC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15109-15114

[4] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

[5] HIV reproducibly establishes a latent infection after acute infection of T cells in vitro [J].

Jordan, A ;

Bisgrove, D ;

Verdin, E .

EMBO JOURNAL, 2003, 22 (08) :1868-1877

[6] The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation [J].

Jordan, A ;

Defechereux, P ;

Verdin, E .

EMBO JOURNAL, 2001, 20 (07) :1726-1738

[7] Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency [J].

Kutsch, O ;

Benveniste, EN ;

Shaw, GM ;

Levy, DN .

JOURNAL OF VIROLOGY, 2002, 76 (17) :8776-8786

[8] Depletion of latent HIV-1 infection in vivo: a proof-of-concept study [J].

Lehrman, G ;

Hogue, IB ;

Palmer, S ;

Jennings, C ;

Spina, CA ;

Wiegand, A ;

Landay, AL ;

Coombs, RW ;

Richman, DD ;

Mellors, JW ;

Coffin, JM ;

Bosch, RJ ;

Margolis, DM .

LANCET, 2005, 366 (9485) :549-555

[9] Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription [J].

Lewinski, MK ;

Bisgrove, D ;

Shinn, P ;

Chen, H ;

Hoffmann, C ;

Hannenhalli, S ;

Verdin, E ;

Berry, CC ;

Ecker, JR ;

Bushman, FD .

JOURNAL OF VIROLOGY, 2005, 79 (11) :6610-6619

[10]

NAIDINI L, 1996, SCIENCE, V272, P263

← 1 2 →